SCHEMBL32667239

SCHEMBL32667239

CN1CCN(Cc2cnc(Br)s2)CC1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.58
TDP1 Q9NUW8 1/20 0.58
ALDH1A1 P00352 3/20 0.46
LMNA P02545 5/20 0.43
RECQL P46063 1/20 0.43
KMT2A Q03164 1/20 0.43
NPC1 O15118 1/20 0.42
HSP90AB1 P08238 1/20 0.41
MC4R P32245 1/20 0.41
SMN1; SMN2 Q16637 3/20 0.40
MAPT P10636 2/20 0.40
POLB P06746 1/20 0.40
PDE2A O00408 1/20 0.40
DRD4 P21917 1/20 0.40
DRD3 P35462 1/20 0.40
GAA P10253 2/20 0.40
SLC8A1 P32418 1/20 0.39
JAK2 O60674 1/20 0.39
JAK1 P23458 1/20 0.39
TYK2 P29597 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1724923 0.84 SMN1; SMN2 (0.49) KDM4ETDP1ALDH1A1LMNARECQL
SCHEMBL10891097 0.83 RECQL (0.50) KDM4ETDP1ALDH1A1LMNARECQL
SCHEMBL3085138 0.83 ALDH1A1 (0.67) KDM4ETDP1ALDH1A1LMNARECQL
SCHEMBL1871497 0.82 SMN1; SMN2 (0.51) KDM4ETDP1ALDH1A1LMNARECQL
SCHEMBL13940675 0.82 ALDH1A1 (0.43) KDM4ETDP1ALDH1A1LMNARECQL
SCHEMBL2112989 0.81 TDP1 (0.49) KDM4ETDP1ALDH1A1LMNARECQL
SCHEMBL28975291 0.81 NPC1 (0.59) ALDH1A1LMNARECQLKMT2ANPC1
SCHEMBL22079383 0.79 SMN1; SMN2 (0.49) KDM4ETDP1ALDH1A1LMNASMN1; SMN2
SCHEMBL14367258 0.79 KMT2A (0.47) KDM4ETDP1ALDH1A1LMNARECQL
SCHEMBL14367255 0.79 KDM4E (0.46) KDM4ETDP1ALDH1A1LMNARECQL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260028365-A1 TYROSINE KINASE 2 INHIBITORS AND USES THEREOF BIOGEN MA INC (US) 2026-01-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260028365-A1 TYROSINE KINASE 2 INHIBITORS AND USES THEREOF TYK2, ERBB2, ROS1 KDM4E 1141/4885TDP1 933/4885ALDH1A1 2989/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.